Table 1 Demographic and clinical characteristics of study cohort and excluded patients
Inclusions (all) | Monophasic | Polyphasic | Persistent | Exclusions | |
|---|---|---|---|---|---|
Number of patients | 65 | 23 | 6 | 36 | 136 |
Female, number | 41 (63%) | 18 (78%) | 4 (80%) | 19 (51%) | 69 (48.6%) |
Age at diagnosis in years | 4.8 (2.4 – 8.5) | 7.3 (1.9 – 10) | 7 (2.9 – 13) | 4.5 (2.6 – 6.5) | 4.5 (2.2 – 9.3) |
Age at disease onset | 4.6 (2.2 – 8.2) | 7.25 (1.6 – 10) | 7 (2.6 – 13) | 3.9 (2.3 – 6.5) | 4.5 (2.2 – 9.3) |
Time from onset of symptoms to diagnosis in months | 1.1 (1 – 4.1) | 1 (0.6 – 2) | 1.1 (0.75 – 3.25) | 2 (1 – 6.75) | 1.8 (0.75 – 4.5) |
Time to inactive disease from diagnosis in months | 14 (3.5 – 37.5) | 7 (2 – 14) | 7 (0.75 – 17.25) | 28 (6 – 72.25) | Not assessed |
Time to follow-up in years | 4.7 (3.1 – 8.3) | 3.7 (2.7 – 5.8) | 4.1 (3 – 5.3) | 6.3 (3.6 – 9.6) | Not assessed |
Arthritis | 59 (91%) | 18 (74%) | 5 (83%) | 35 (97%) | 113 (83%) |
Oligoarthritis | 29 (45%) | 11 (48%) | 3 (50%) | 14 (39%) | 39 (29%) |
Polyarthritis | 29 (45%) | 6 (26%) | 2 (33%) | 21 (58%) | 72 (53%) |
Fever | 64 (99%) | 23 (100%) | 6 (100%) | 35 (97%) | 117 (86%) |
Rash | 46 (71%) | 18 (78%) | 4 (67%) | 24 (67%) | 106 (78%) |
Lymphadenopathy | 26 (41%) | 9 (41%) | 2 (33%) | 15 (42%) | 58 (43%) |
Hepatomegaly | 11 (17%) | 4 (17%) | 1 (17%) | 6 (17%) | 24 (18%) |
Splenomegaly | 14 (22%) | 8 (35%) | 1 (17%) | 5 (14%) | 22 (16%) |
Serositis | 12 (19%) | 2 (9%) | 2 (33%) | 8 (23%) | 21 (15%) |